Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients

Inclusion Criteria

Subjects/patients must meet all inclusion criteria to be eligible for study participation.

• Males or females ≥ 18 years of age.
• Females must be of non-childbearing potential (eg, postmenopausal [defined cessation of regular menstrual periods for at least 1 year confirmed by age => 60 or surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation [documentation required]) or be using a medically acceptable form of birth control (a barrier method, intrauterine device, or hormonal contraception) from screening through 30 days after administration of the last dose of VFI.
• Males who are sexually active and whose partners are females of childbearing potential must agree to practice abstinence or use condoms from screening through 90 days after administration of the last dose of VFI, and their partners must be willing to use a medically acceptable method of contraception (a barrier method, intrauterine device, or hormonal contraception) from screening through 90 days after administration of the last dose of VFI.
• Males must agree to not donate sperm from screening through 90 days after administration of the last dose of VFI.
• Subjects/patients must be able to communicate effectively with the study personnel.
• Patients must be on chronic hemodialysis for >= 3 months and oliguric defined as 450 mL) or has donated 1 or more units of blood or plasma within 4 weeks prior to study participation.
• Presence of significant hemodynamic instabilities defined as systolic BP <100 on dialysis requiring saline infusion in the past 4 weeks.
• Presence of ascites and/or 4+ anasarca.
• Any other condition or prior therapy that, in the investigator's opinion, would make the subject unsuitable for the study, or unable or unwilling to comply with the study procedures.
• Involved in the planning or conduct of this study.
• Unwilling or unlikely to comply with the requirements of the study.
• Clinically significant ongoing bleeding, changing hemoglobin, or experienced significant blood loss within the last 4 weeks.
• Had a PRBC transfusion in the prior 2 weeks
• Use of midodrine.
• Any other condition or prior therapy that, in the investigator's opinion, is likely to deteriorate during study participation
• Subjects suffering from significant non-cardiac diseases of other organ systems (e. g. Malignancies, significant neurological diseases).
• Subject has a psychiatric disease or a history of illicit drug use that would prohibit them from complying with study requirements.
• Use of hemodialysis catheter as primary vascular access for hemodialysis